Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge. This randomized controlled study assesses whether remote monitoring can improve treatment adherence, clinical outcomes, and side effect management in PAH patients on oral therapy.
Adults aged ≥18 years diagnosed with pulmonary arterial hypertension (PAH) (Group 1 of the WHO classification).
Stable oral PAH therapy (including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin pathway agents) for at least four weeks prior to enrollment.
Ability to participate in remote teleconsultations (access to a phone or internet).
Signed informed consent agreeing to study participation.
Severe cognitive impairment or psychiatric disorders that could affect adherence or study participation.
Inability to communicate via phone or telemedicine due to technical or personal constraints.
Concurrent participation in another interventional clinical trial that could interfere with outcomes.
Life expectancy <6 months due to any condition unrelated to PAH.